ASA reduced VTE risk

In this large multi center study, patients with an unprovoked VTE who had already completed 6-18 months of anticoagulation were randomized to ASA 100mg/day or placebo for 2 years. The risk of recurrent VTE was 11% in the placebo group and 7% in the ASA group (hazard ratio 0.58, CI 0.36 to 0.93), with no difference between groups in bleeding or adverse events. This should change current practice, and promote long term use low dose ASA after initial anticoagulation in patients with unprovoked VTE (abstract)